Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking Alzheimer's Origins: Antimicrobial Amyloid and Tau Point to Potential Upstream Immune Triggers.

Neuroscience bulletin·2026
Same author

Model-Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma.

Clinical pharmacology and therapeutics·2026
Same author

When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development.

Clinical and translational science·2026
Same author

Prognostic Model-Guided Randomization Improves Efficiency in Early-Phase Trials: Evidence From Surveys and Simulations.

Clinical and translational science·2026
Same author

Assessing Potential Benefit of Stroke Prophylaxis Therapy in Atrial Fibrillation and Atrial Flutter Using a Novel Competing Risk Scoring Tool.

Journal of the American Heart Association·2026
Same author

Antibody Transfer From Mother to Fetus/Infant: An Opportunity for Model-Informed Precision Medicine.

Journal of clinical pharmacology·2025

Related Experiment Video

Updated: Mar 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K

Quantitative Lesion-Level Modeling Reveals Organ-Dependent Therapeutic Response.

Ian Dilley1, Jiawei Zhou1,2, Quefeng Li3

  • 1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Clinical Pharmacology and Therapeutics
|March 13, 2026
PubMed
Summary

This study introduces a new modeling framework to analyze metastatic lesion behavior at the organ level. It reveals that metastatic site significantly impacts treatment response durability and progression risk, improving cancer drug development insights.

More Related Videos

Brain Infarct Segmentation and Registration on MRI or CT for Lesion-symptom Mapping
10:25

Brain Infarct Segmentation and Registration on MRI or CT for Lesion-symptom Mapping

Published on: September 25, 2019

49.6K
Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.6K

Related Experiment Videos

Last Updated: Mar 14, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Brain Infarct Segmentation and Registration on MRI or CT for Lesion-symptom Mapping
10:25

Brain Infarct Segmentation and Registration on MRI or CT for Lesion-symptom Mapping

Published on: September 25, 2019

49.6K
Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.6K

Area of Science:

  • Oncology
  • Pharmacometrics
  • Translational Medicine

Background:

  • Current RECIST criteria limit understanding of organ-specific drug effects on metastatic lesions.
  • This limitation hinders accurate efficacy signal interpretation for drug development and clinical decisions.

Purpose of the Study:

  • To develop a lesion-level modeling framework for quantifying compartment-dependent therapeutic effects.
  • To assess the independent contribution of metastatic site to response and progression hazards across cancer types.

Main Methods:

  • Utilized nonlinear mixed-effects modeling to analyze lesion trajectories and estimate key kinetic parameters (kkill, kge, Fx).
  • Applied pan-cancer multivariable Cox models, adjusting for clinical covariates, to evaluate metastatic site effects.
  • Correlated organ-specific Vascular Perfusion and Leakiness Index (VaPLI) and immune surveillance with treatment outcomes.

Main Results:

  • Metastatic site is a consistent determinant of response durability across cancer lineages.
  • Liver metastases showed rapid shrinkage but higher progression risk; bone metastases demonstrated slower regression but durable control.
  • Vascular Perfusion and Leakiness Index (VaPLI) correlated with response probability, and immune-tolerant sites had higher progression hazards.

Conclusions:

  • A lesion-level modeling approach can differentiate true treatment effects from site-driven biases in efficacy evaluation.
  • Organ site significantly influences metastatic lesion response dynamics and progression, impacting drug development and clinical decision-making.
  • This framework supports lesion site-stratified efficacy evaluation for more balanced interpretation of treatment effects and dose-response relationships.